New drug avoids treatment problem for hepatitis C patients

10/31/2006 | HealthDay News

Researchers say hepatitis C patients with cirrhosis and low platelet levels can take standard antiviral medications if they also use the new drug eltrombopag. Two common drugs, ribavirin and pegylated interferon, further reduce platelet levels in patients, but eltrombopag counters that effect.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT